Rybrevant Faspro won accelerated approval for recurrent or metastatic HNSCC after a trial showed a 42% response rate in previously treated patients.
|Podcasts|October 13, 2021
Kevin Hrusovsky of Quanterix Shares Successful Tools Toward Improving Precision Health and More
Author(s)Briana Contreras
In this week’s episode, Managed Healthcare Executive Associate Editor Briana Contreras had the pleasure of meeting CEO of Quanterix and founder of Powering Precision Health, Kevin Hrusovsky. Quanterix is a blood-based biomarker analysis company. In this discussion, the two discussed Powering Precision Health and some tools like the Disruptive Innovation 5-step model that brings his vision closer of detecting and improving the health of patients sooner.
Advertisement
To listen to more episodes featured on Tuning Into The C-Suite, visit us on
Advertisement
Related to this article
David Feldshon, M.D., a Yale gastroenterologist who still performs endoscopy two days a week at 75, discusses his approach to MASLD and life outside the clinic.
Researchers in Lyon, France, conducted a retrospective cohort study of intensifying the dosing of biologics such as Humira, adding oral antibiotics, or both as ways to boost the response of patients with hidradenitis suppurativa.
Expect Democrats to flex their oversight powers even if President Donald Trump’s veto power blocks their efforts to reverse Medicaid cuts or restore enhanced ACA subsidies. The administration’s most-favored-nation policies and HHS Secretary Kennedy will probably be in the hot seat.
Health plans should be using data, digital tools and human support to identify potential disruptions early, and whether a member is changing plans or managing a new health condition, the experience should feel guided rather than overwhelming.
Pretax adjusted income from operations from Express Scripts, Cigna's pharmacy benefit manager, fell by 21.5% compared with the third quarter of 2025, while income from operations of its specialty drug business jumped by 15%.
Annesha White, Pharm.D., M.S., Ph.D., and Fredrick Manasseh, Pharm.D., MBA, BCGP, explain where AI helps managed care pharmacy, where bias creeps in and what skills pharmacists need to oversee it.
Teva’s Weltruza delivers olanzapine monthly under the skin, with no loading doses, oral supplementation or post-injection monitoring required.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
WHO adds two Bundibugyo vaccines to Ebola trial in the DRC
2
Cigna’s third-quarter earnings show a drop in income from its pharmacy benefit business
3
Christopher Stanley, M.D., MBA, on culture change and implementing value-based care
4
After a 10-year gap, FDA approves new option for pretreated head and neck cancer
5